Imipenem/cilastatin/relebactam
Combination drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Imipenem/cilastatin/relebactam?
Summarize this article for a 10 year old
Imipenem/cilastatin/relebactam, sold under the brand name Recarbrio,[1] is a fixed-dose combination medication used as an antibiotic. In 2019, it was approved for use in the United States for the treatment of complicated urinary tract and complicated intra-abdominal infections.[3][4][5][6] It is administered via intravenous injection.[7][1]
Combination of | |
---|---|
Imipenem | β-Lactam antibiotic |
Cilastatin | Dehydropeptidase inhibitor |
Relebactam | β-Lactamase inhibitor |
Clinical data | |
Trade names | Recarbrio |
Other names | MK-7655A |
AHFS/Drugs.com | Monograph |
MedlinePlus | a619046 |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
The most common adverse reactions include nausea, diarrhea, headache, fever and increased liver enzymes.[3]
The most common adverse reactions observed in people treated for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) include increased aspartate/alanine aminotransferases (increased liver enzymes), anemia, diarrhea, hypokalemia (low potassium), and hyponatremia (low sodium).[8]